/ /

  • linkedin
  • Increase Font
  • Sharebar

    New glaucoma therapy offers first drug option in years

    Latanoprostene bunod increases outflow through the trabecular meshwork and Schlemm's canal


    IOP-reducing option

    According to the prescribing information, latanoprostene bunod begins reducing IOP within three hours after administration, and the maximum effect is achieved after 11 to 13 hours in the eye.

    “This drop might be used in situations where future tolerability is a concern,” Dr. Bacharach said. “So if a patient is on a prostaglandin, such as latanoprost, is not having issues with tolerability but still needs an additional boost in IOP reduction, this might be an excellent tool.”

    But clinicians “do not know how this drug works relative to other prostaglandins,” Dr. Bacharach said. “We don't know how well it works in combination with other classes of agents.”

    In the VOYAGER study1, latanoprostene bunod lowered mean diurnal IOP by 1.23 mm Hg more than latanoprost 0.005% at day 28. While VOYAGER was a phase II, dose-ranging study, other large scale randomized trials have been open-label and found similar results.2

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results